Transition Bio

Cambridge, United States

Transition Bio provides condensate technology for drug discovery and diagnostics.

$13.3M raised

Oct 2024

Venture - Series Unknown

Biotechnology Health Care Health Diagnostics Medical

Top Investors

Bristol-Myers SquibbNorthpond VenturesTaiho VenturesLifeforce CapitalMagnetic Ventures

Founder Contacts

19,000+ verified contacts

Get Instant Access

Emails, phones & LinkedIn profiles

Frequently Asked Questions about Transition Bio

How much funding has Transition Bio raised?

Transition Bio has raised $13.3M in total funding. The most recent round was Venture - Series Unknown. The last funding was announced in October 2024.

Who are Transition Bio's investors?

Transition Bio's investors include Bristol-Myers Squibb, Northpond Ventures, Taiho Ventures, Lifeforce Capital, Magnetic Ventures.

Where is Transition Bio headquartered?

Transition Bio is headquartered in Cambridge, United States.

What does Transition Bio do?

Transition Bio provides condensate technology for drug discovery and diagnostics.

What stage is Transition Bio at?

Transition Bio is at the Venture - Series Unknown stage.

Cite this page

Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated October 24, 2024.

MLA

"Transition Bio — Funding & Investors." VCBacked, October 24, 2024, https://www.vcbacked.co/company/transition-bio. Accessed June 3, 2026.

APA

VCBacked. (2024). Transition Bio — Funding & Investors. Retrieved June 3, 2026, from https://www.vcbacked.co/company/transition-bio

Wikipedia (cite web)

{{cite web |title=Transition Bio — Funding & Investors |url=https://www.vcbacked.co/company/transition-bio |website=VCBacked |access-date=June 3, 2026}}

Profile data sourced and verified per the VCBacked methodology. Last funding round dated October 24, 2024.